# Effect of BM-MSCs on Chronic AMR After Kidney Transplantation

> **NCT02563340** · PHASE1,PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 60 (estimated)

## Conditions studied

- Kidney Transplantation

## Interventions

- **OTHER:** BM-MSCs
- **OTHER:** Desensitization therapy (PP, IVIG, rituximab or Bortezomib)

## Key facts

- **NCT ID:** NCT02563340
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2017-10
- **Final completion:** 2017-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563340, "Effect of BM-MSCs on Chronic AMR After Kidney Transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02563340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*